Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.45 |
| ▸ | PROKR2 | Q8NFJ6 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10254261 | 0.89 | PROKR1 (0.53) | MAPTPROKR1PROKR2DCTPP1ALDH1A1 | |
| SCHEMBL325288 | 0.85 | PROKR1 (0.54) | MAPTSMN1; SMN2PROKR1PROKR2ALDH1A1 | |
| SCHEMBL326197 | 0.85 | PROKR1 (0.60) | MAPTPROKR1PROKR2ALDH1A1 | |
| SCHEMBL326653 | 0.84 | PROKR1 (0.55) | MAPTSMN1; SMN2PROKR1PROKR2KMT2A | |
| SCHEMBL8280056 | 0.81 | PROKR1 (0.57) | SMN1; SMN2PROKR1PROKR2DCTPP1 | |
| SCHEMBL325491 | 0.78 | PROKR1 (0.76) | PROKR1PROKR2 | |
| SCHEMBL10254322 | 0.76 | PROKR1 (0.42) | SMN1; SMN2PROKR1PROKR2L3MBTL1ALDH1A1 | |
| SCHEMBL325883 | 0.75 | PROKR1 (0.47) | MAPTSMN1; SMN2PROKR1PROKR2KMT2A | |
| SCHEMBL10254173 | 0.75 | MAPT (0.50) | MAPTSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL325602 | 0.75 | P2RX3 (0.49) | PROKR1PROKR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585068-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | disclosed |
| EP-1866290-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-01 | — | — | EP | disclosed |
| US-8362247-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-29 | — | — | US | disclosed |
| US-8362247-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-29 | — | — | US | disclosed |
| US-8362247-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-29 | — | — | US | disclosed |
| US-20120245077-A1 | PROKINETICIN 1 RECEPTOR | MABUS JOHN R (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245077-A1 | PROKINETICIN 1 RECEPTOR | MABUS JOHN R (US) | 2012-09-27 | — | — | US | disclosed |
| US-8188081-B2 | Methods of treating inflammation using prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-8188081-B2 | Methods of treating inflammation using prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-20120129862-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-05-24 | — | — | US | disclosed |
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| EP-1869006-A1 | PYRIMIDINDIONE DERIVATIVES AS PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1866290-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-19 | — | — | EP | disclosed |
| US-20070021422-A1 | Prokineticin 1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021422-A1 | Prokineticin 1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021422-A1 | Prokineticin 1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20060235018-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-19 | — | — | US | disclosed |
| WO-2006104715-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006104713-A1 | PYRIMIDINDIONE DERIVATIVES AS PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | MAPT 4073/4885SMN1; SMN2 2454/4885KCNJ1 2925/4885 |
| US-20060235018-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | MAPT 4202/4885SMN1; SMN2 2677/4885KCNJ1 3038/4885 |
| US-20120129862-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | MAPT 4202/4885SMN1; SMN2 2677/4885KCNJ1 3038/4885 |
| US-20070021422-A1 | Prokineticin 1 receptor | PROKR1, PROKR2, GIPR | MAPT 4644/4885SMN1; SMN2 2519/4885KCNJ1 2018/4885 |
| US-20120245077-A1 | PROKINETICIN 1 RECEPTOR | PROKR1, PROKR2, GIPR | MAPT 4644/4885SMN1; SMN2 2519/4885KCNJ1 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.